First generic version of EpiPen approved by FDA

Teva's generic EpiPen injector received a thumbs up from the FDA on Thursday.

David Gideon, medical media icon and industry stalwart, dies at 75

For Gideon, honoring those who helped build the medical ad industry became a labor of love.

Study: FDA anti-tobacco campaign prevented 350,000 teens from smoking

The study estimated the FDA's anti-smoking campaign, The Real Cost, saved $31 billion in smoking-related costs to society.

Q&A: Matt McNally on the road ahead for Outcome Health and the state of the POC union

Q&A: Matt McNally on the road ahead for Outcome Health and the state of the POC union

Matt McNally, CEO of Outcome Health, shares his thoughts on post-controversy Outcome Health and the overall state of the point-of-care union.

Media buyers form group to advance standards in POC

Media buyers form group to advance standards in POC

Among the group's members are media agencies that had pulled healthcare ad spend from the POC channel in the wake of a scandal 10 months ago.

POC community makes good on promises of transparency and accountability

POC community makes good on promises of transparency and accountability

After a scandal with one of point of care's biggest players, we examine how the community is living up to its promise of greater transparency.

Five things for pharma marketers to know: Friday, August 17, 2018

Five things for pharma marketers to know: Friday, August 17, 2018

Purdue Pharma taps financial restructuring firm; White House wants opioid-production cut; NYU to make med school free.

Five things for pharma marketers to know: Thursday, August 16, 2018

Five things for pharma marketers to know: Thursday, August 16, 2018

CDC estimates 72,000 died of drug overdoses in 2017; Genentech to lay off 200-plus employees; Pfizer invests up to $425 million in BioNTech.

Five things for pharma marketers to know: Wednesday, August 15, 2018

Five things for pharma marketers to know: Wednesday, August 15, 2018

Alphabet invests more in Oscar; ViiV's HIV injection proves effective; Gilead's chief medical officer departs in latest executive exit.

Novartis names Klaus Moosmayer ethics, risk, and compliance chief

Novartis names Klaus Moosmayer ethics, risk, and compliance chief

Moosmayer is set to join the pharma company in December.

Healix's Jeffrey Erb on what pharma giants consolidating accounts means for agencies

Healix's Jeffrey Erb on what pharma giants consolidating accounts means for agencies

Bigger budgets, fewer accounts. That's the dilemma facing pharma marketers as drugmakers consolidate work.

Five things for pharma marketers to know: Tuesday, August 14, 2018

Five things for pharma marketers to know: Tuesday, August 14, 2018

Icahn drops bid to stop Cigna-Express Scripts tie-up; Bayer joins Evotec-Haplogen partnership to find COPD treatments; Orchard raises $150 million in Series C funding.

WPP leaves Farm Street HQ as it cuts links with Sorrell era

WPP leaves Farm Street HQ as it cuts links with Sorrell era

WPP is set to depart its London headquarters in Farm Street after more than 30 years as it seeks "a more modern and attractive office."

Novartis ups Sreejit Mohan to global head of external communications

Novartis ups Sreejit Mohan to global head of external communications

Mohan was previously head of global drug-development communications.

Five things for pharma marketers to know: Monday, August 13, 2018

Five things for pharma marketers to know: Monday, August 13, 2018

Bayer shares fall after Monsanto weedkiller judgment; FDA approves first birth-control app to be marketed as contraception method; Regulators okay landmark RNAi-based therapy.

Marketing a first-of-its-kind addiction treatment amid the opioid crisis

Marketing a first-of-its-kind addiction treatment amid the opioid crisis

The first non-opioid opioid-withdrawal treatment, Lucemyra, hit the market this week.